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Abstract
Background: Lantibiotics are heat-stable peptides characterized by the presence of thioether amino acid lanthionine
and methyllanthionine. They are capable to inhibit the growth of Gram-positive bacteria, including Listeria
monocytogenes, Staphylococcus aureus or Bacillus cereus, the causative agents of food-borne diseases or
nosocomial infections. Lantibiotic biosynthetic machinery is encoded by gene cluster composed by a structural gene
that codes for a pre-lantibiotic peptide and other genes involved in pre-lantibiotic modifications, regulation, export and
immunity.
Methodology/Findings: Bacillus amyloliquefaciens GA1 was found to produce an antimicrobial peptide, named
amylolysin, active on an array of Gram-positive bacteria, including methicillin resistant S. aureus. Genome
characterization led to the identification of a putative lantibiotic gene cluster that comprises a structural gene (amlA)
and genes involved in modification (amlM), transport (amlT), regulation (amlKR) and immunity (amlFE). Disruption of
amlA led to loss of biological activity, confirming thus that the identified gene cluster is related to amylolysin
synthesis. MALDI-TOF and LC-MS analysis on purified amylolysin demonstrated that this latter corresponds to a
novel lantibiotic not described to date. The ability of amylolysin to interact in vitro with the lipid II, the carrier of
peptidoglycan monomers across the cytoplasmic membrane and the presence of a unique modification gene suggest
that the identified peptide belongs to the group B lantibiotic. Amylolysin immunity seems to be driven by only two
AmlF and AmlE proteins, which is uncommon within the Bacillus genus.
Conclusion/Significance: Apart from mersacidin produced by Bacillus amyloliquefaciens strains Y2 and HIL
Y-85,544728, reports on the synthesis of type B-lantibiotic in this species are scarce. This study reports on a genetic
and structural characterization of another representative of the type B lantibiotic in B. amyloliquefaciens.
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Introduction
Bacteriocins are antimicrobial peptides ribosomally
synthesized capable to inhibit the growth of Gram-positive
bacteria, including Listeria monocytogenes, Staphylococcus
aureus or Bacillus cereus, the causative agents of food-borne
diseases or nosocomial infections [1,2]. The class I
bacteriocins, the so-called lantibiotics, are heat stable post-
translationally modified peptides that contain multiple thioether
amino acids lanthionine (Lan) and methyllanthionine (Melan)
[3]. These latter are respectively enzymatically synthesized
from a cysteine thiol and the dehydrated dehydroalanine (Dha)
or didehydrobutyrine (Dhb) amino acids [4].
Lantibiotics could be subdivided into two main subgroups:
type-A lantibiotics that exhibit a linear secondary structure and
are positively charged at neutral pH. They are modified by two
distinct LanB and LanC enzymes and processed by a LanP
protease. Type-B lantibiotics, conversely, exhibit a globular
structure and are non-charged or slightly negatively charged at
neutral pH. They are modified by a single modification LanM
enzyme and processed by a LanT ABC transporter with N-
terminal-associated protease activity [5]. Type-B subgroup also
includes the so-called two-component lantibiotics consisting of
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two synergistically acting peptides that are modified by a single
LanM-type enzyme [6]. Recently, a third Type-C subgroup has
been reported. It corresponds to peptides, such as SapT and
SapB from Streptomyces tendae, that present mainly a
morphogenetic function rather than an antimicrobial activity.
Beside this, lantibiotic could also be distinguished based on
their biological mode of action. Some, such as mersacidin, bind
to lipid II and thereby inhibit peptidoglycan cell wall synthesis in
sensitive Gram-positive bacteria [7] while others, such as
Pep5, form pores in cytoplasmic membrane that lead to cell
leakage and finally to cell death [8,9]. A third group of
compounds is formed by lantibiotic that possess a dual mode
of action, i.e. inhibition of the peptidoglycan biosynthesis and
pore forming. Both mode of action could be ensured by a single
peptide (such as nisin) or by two distinct peptides in two-
component lantibiotic, such as lacticin 3147 [10].
Lantibiotic peptides are gene encoded and their structural
genetic determinants are found in biosynthetic gene clusters.
They are synthesized as inactive prepeptides, with a N-terminal
leader sequence separated from the mature lantibiotic [3]. In
type A lantibiotics, many of the leader peptides end with a PQ
or PR sequence and share a conserved F(N/D)LD motif in their
core sequence. On the other hand, leader peptides of type-B
lantibiotics end with G(G/A/S) sequence [6]. They are not
processed by a LanP protease such as in type-A lantibiotic but
by the N-terminal intracellular domain of LanT protein [11]. In
addition, all lantibiotic gene clusters encode a set of immunity
proteins that protect the producer strain against the biological
effect of the synthesized lantibiotic. Depending on the
lantibiotic considered, these immunity proteins could be LanI,
LanF, LanE or LanG [12]. Regulation of lantibiotics
biosynthesis is mediated by regulatory LanR and LanK proteins
that constitute a two-component signal transduction system
[13].
Despite the majority of the lantibiotics described so far are
from lactic bacteria, Bacillus represents an alternative genus to
investigate for antimicrobial peptides because it includes many
industrial species and has a history of safe use in the food
industry [14]. There are few reports on lantibiotic synthesis in
B. amyloliquefaciens. Production of mersacidin, a type-B
lantibiotic, has been reported in B. amyloliquefaciens subsp
plantarum B6901-Y2 and B. amyloliquefaciens HIL Y-85,54728
(formerly Bacillus sp. HIL Y-85,54728) [7,15,16]. The
biosynthetic cluster involved in mersacidin biosynthesis is
composed of ten genes that span over 12.3 kb in the genome
[6]. The biological mode of action of mersacidin is related to its
ability to bind to the lipid II and thus to prevent peptidoglycan
biosynthesis [7].
Recently, we have identified Bacillus amyloliquefaciens GA1
as a producer of a proteinaceous compound with potent
antimicrobial activity toward the foodborne pathogen Listeria
monocytogenes [17]. The failure of structural gene detection for
all the genetically described bacteriocins from the Bacillus
genus strongly suggests that this antimicrobial peptide, named
amylolysin, corresponds to a novel bacteriocin not described to
date. Prior intensive characterization, amylolysin was purified
to test its ability to inhibit the growth of L. monocytogenes in
poultry meat upon long-term storage [17]. In the present paper,
we report on the biochemical characterization of that novel
bacteriocin, the nucleotide sequence of the gene cluster
involved in its biosynthesis and peculiar features on its
inhibition spectrum and structural traits.
Results
Inhibition spectrum
The biological activity of the purified amylolysin was
characterized by determining the minimal inhibitory
concentration (MIC) for an array of bacterial and fungal
indicator strains. As shown in table 1, amylolysin showed an
antibacterial spectrum directed toward Gram-positive bacteria.
Indeed, no growth inhibition was observed in our experimental
conditions neither on both Basidiomycetous and Ascomycetous
yeasts (i.e. Cryptococcus neoformans and Saccharomyces
cerevisiae, respectively), nor on Gram-negative bacterium (i.e.
Escherichia coli and Pseudomonas aeruginosa). By contrast, a
significant inhibitory effect was observed for Enterococcus
faecium with a MIC value of 0.1 µM and for Enterococcus
faecalis in a lesser extent. Among the Bacillus genus, the
opportunistic pathogen B. cereus that is a common cause of
food poisoning was also found very sensitive with an MIC value
of 0.2 µM. The growth of L. monocytogenes, another major
food poisoning bacteria was also found sensitive to amylolysin
with an MIC value close 0.5 µM for the three clinical or food
isolates tested, confirming thus previous observation [17]. S.
aureus, including methicillin-resistant isolates (0.4 µM),
together with S. epidermidis (2.8 µM), which are both
opportunistic human pathogens, were also found sensitive to
amylolysin. For lactic acid bacteria such as Weissella sp. and
Lactobacillus plantarum, only a weak or no growth inhibition
effect was observed in our experimental conditions.
Amylolysin susceptibility to proteases, heat and pH
Incubation of purified amylolysin with pronase and proteinase
K led to a strong decrease of the antimicrobial activity against
the indicator strain Micrococcus luteus ATCC 9341 (Table 2).
By contrast, no significant reduction of the amylolysin biological
activity against the indicator strain was observed upon heat
treatments at different temperatures or incubation at various pH
(Table 2). Indeed, incubation of purified amylolysin at 100 °C
for 1 hour, led only to a 7% reduction of its biological activity
whereas incubation in acidic (pH 2) and alkaline (pH9)
condition led to an 11% and 7% antimicrobial activity reduction,
respectively. These results were further confirmed by the
comparison of the HPLC chromatograms corresponding to
treated and non-treated amylolysin samples (data not shown).
This demonstrates that amylolysin correspond to a heat and pH
stable proteinaceous compound.
Gene cluster sequencing and characterization
In silico analysis of the 461.5 kb fragment of the B.
amyloliquefaciens GA1 chromosome, obtained by partial
shotgun sequencing [18], led to the identification of a 800 bp
fragment encoding an amino acid sequence that exhibits 38 %
and 33 % identity with the lantibiotic modification enzyme from
Characterization of the Lantibiotic Amylolysin
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Bacillus licheniformis ATCC 14580 (Genbank identifier (GI):
304557386) and Bacillus halodurans C-125 (GI: 15613018),
respectively. Further characterization of this locus led to the
identification of different genes homologous to genes involved
in lantibiotic biosynthesis. Indeed, from a 5.5 kb fragment
obtained by inverse polymerase chain reaction (IPCR) [19],
four complete ORFs were identified (Figure 1A). Of these, the
so-called amlA codes for a polypeptide of 60 residues that
presents 35 % and 40 % of identity with the MrsA mersacidin
peptide from B. amyloliquefaciens HIL Y-85,54728 and Bacillus
pseudomycoides DSM 12442, respectively. A detailed analysis
of AmlA sequence revealed the presence of a GG sequence
corresponding to the signal peptidase cleavage site of type-B
lantibiotics (Figure 1B). The GxxxxTx(S/T)x(D/E)C(3-10)xC
motif present in all mersacidin and lacticin 481 like peptides
was also observed together with the CTxTxEC amino acid
sequence known as essential for interactions with the
peptidoglycan biosynthesis precursor lipid II [20,21]. Located
downstream of amlA, amlM encodes a putative 908 amino
acids protein that exhibits 30 % of identity with the lantibiotic
modifying enzyme LchM1 from Bacillus licheniformis ATCC
14580. Multiple sequence alignment of AmlM N-terminal
Table 1. Inhibition spectrum of amylolysin.
Strains
Culture medium,Temperature
(°C)   MIC (µM)
Micrococcus luteus ATCC 9341 BH, 37 0.7
Staphylococcus epidermis ATCC
1228 BH, 37 2.8
Staphylococcus aureus ATCC 25923 BH, 37 2.8
Staphylococcus aureus ATCC 43300a BH, 37 0.4
Staphylococcus aureus RFB127 b BH, 37 1.4
Enterococcus faecalis ATCC 29212 BH, 37 1.4
Enterococcus faecalis RFB129 c BH, 37 0.7
Enterococcus faecium RFB128 b BH, 37 0.1
Listeria monocytogenes LMG 23905 BH, 37 0.4
Listeria monocytogenes LMG 21263 BH, 37 0.5
Listeria monocytogenes LM2234 c BH, 37 0.4
Listeria innocua ATCC33090 BH, 37 0.7
Listeria innocua RFB159c BH, 37 0.7
Listeria ivanovii RFB160 BH, 37 0.8
Bacillus cereus RFB125 c LB, 37 0.2
Bacillus subtilis ATCC 6633 LB, 37 1.4
Bacillus megaterium RFB124 LB, 37 0.4
Streptococcus agalactiae RFB141 c BH, 37 2.8
Weissella sp RFB139 b MRS, 27 2.8
Lactobacillus plantarum RFB138 b MRS, 27 >2.8
Escherichia coli RFB149 c LB, 37 >2.8
Pseudomonas aeruginosa RFB148 b LB, 37 >2.8
Cryptococcus neoformans IHEM3969 YPD, 30 >2.8




LMG and IHEM: http://bccm.belspo.be.
doi: 10.1371/journal.pone.0083037.t001
domain (residues 64 to 364) with other homologous
modification enzymes highlights the presence of the conserved
motifs previously described for this type of enzymes (Figure
S1) [6,22].
Beside this, amlK and amlR, located upstream of amlA were
found to encode proteins that present strong similarities with
two-component regulatory proteins. AmlK shows 32 % of
identity with C-terminal cytoplasmic domain of the Bacillus
subtilis 168 histidine kinase ComP that acts as a membrane
sensor of environmental signals. In this conserved domain,
His30 and Asp161 are the autophosphorylated residue and the
catalytic amino acid conserved in NisR, SpaR and ComP
histidine kinases, respectively [23,24]. In addition, the
conserved glycine rich stretch was found between amino acid
163 and 203 [13,24] (data not shown). AmlR exhibits a 46 % of
identity with transcriptional regulators belonging to LuxR family
(GI: 251795068). Indeed, in its N-terminal sequence, the
characteristic K3ILxxDD9 and L49xxLD53 motifs (including
catalytic residues Asp9 and Asp53) and the lysine residue
(Lys153) of response regulators are found.
In the nucleic acid fragment obtained by IPCR, the
amylolysin immunity and transport genes are missing. To
identify these later, a BlastX search through prokaryotic protein
databases was performed by using the 5.5 kb fragment as the
query sequence. For amlK, amlR and amlM, a high identity
(100% on nucleotide level) was found with sequences from
Bacillus amyloliquefaciens IT45 annotated as sensor histidine
kinase (GI: 363725376), LuxR family transcriptional regulator
(GI: 363725375) and putative LanM like protein (GI:
363725373), respectively. To obtain the missing sequence of
Table 2. Amylolysin stability.




















a Values were normalised as a percentage of the value obtained at physiological
pH
b Values were normalised as a percentage of the value obtained at 25°C
doi: 10.1371/journal.pone.0083037.t002
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the amylolysin biosynthetic gene cluster, primer walking was
performed using B. amyloliquefaciens IT45 genome sequence
as a template (GI: 423191475). This led to the identification of
a 1.9 and 2.1 kb fragment upstream and downstream of amlK
and amlA, respectively (Figure 1). Of these, three ORFs,
designated as amlT, amlF and amlE, were identified and the
deduced amino acid sequences are identical to those present
in the B. amyloliquefaciens IT45 sequence and annotated as
ABC transporter-like protein (GI: 363725372), efflux ABC
transporter ATP-binding protein (GI: 363725380) and
hypothetical protein KSO14349 (GI: 363725379), respectively.
A search for specific motifs in these three amino acid
sequences highlights the following similarities. The N-terminal
part of AmlT belongs to C39 bacteriocin-processing peptidase
superfamily [11]. More precisely, Cys19, His97 and Asp113 were
identified as the putative catalytic amino acids conserved in
these peptidases (data not shown) [25]. Beside this, the C-
terminal part of AmlT sequence was found to exhibit similarities
with ABC transporter superfamily, suggesting its role in
amylolysin transport (data not shown). AmlE exhibits 36%
identity with the membrane-bound part of a lantibiotic ABC
transporter (GI: 260687109) from Clostridium difficile R20291,
whereas AmlF shows 44% identity with MrsF (GI: 385266873)
from Bacillus sp. 5B6, involved in lantibiotic self-protection.
This latter contains a conserved domain of ABC transporter
and belongs to the P-loop NTPase superfamily (data not
shown) [26]. Therefore, it is likely that AmlE and AmlF could be
involved in immunity mechanism with AmlF being the ATP-
binding subunit and AmlE the efflux protein of an ABC
transporter. The different aml gene sequences were deposited
at GenBank under the accession number KC415250.1 (GI:
448918122).
Disruption of amlA gene
In order to correlate the antimicrobial activity of amylolysin to
the putative lantibiotic gene cluster, the structural amlA gene
was disrupted by insertion of a kanamycin resistance gene into
amlA by double homologous recombination (Figure 1A).
Culture supernatant of the resulting RFB137 insertion mutant
(Table S1) was characterized by a loss of antibacterial activity
Figure 1.  Characterization of the amylolysin gene cluster.  (A). The gene coding for the amylolysin prepeptide (amlA) is colored
in grey. The other genes are marked with the following patterns: immunity (amlEF) in blue, regulation (amlKR) in yellow,
modification (amlM) in green and transport in orange. Stripes arrow corresponds to the Kan construct used for amlA disruption.
Putative promoters and terminators are indicated by vertical arrows and red symbol, respectively. (B) Primary structure of amlA
gene. Predicted -10box and -35box are in red, ribosome binding site (RBS) is in blue and predicted terminator of amlKR cluster is in
green. The four-glycine stretch is underlined and the highly conserved motif CTLTXEC is in bold blue. (C) Amino acid alignment of
AmlA with LanA1 peptides of the two-peptide lantibiotics haloduracin (HalA1, DAB04173) and lacticin 3147 (LtnA1, O87236).
Conserved amino acids are in bold blue; those forming the CTLTXEC motif are in bold and underlined. The thioether bridging
patterns represents that of HalA1.
doi: 10.1371/journal.pone.0083037.g001
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against M. luteus ATCC 9341 compared to that of the wild-type
strain (Figure 2, insert). To further characterize the mutant
phenotype, concentrated culture supernatant from RFB137
strain were analyzed by RP-HPLC and compared to that of the
parental strain. As shown in Figure 2, the 21.5 min peak
corresponding to amylolysin is lacking for RFB137 sample
confirming that identified locus is involved in amylolysin
biosynthesis.
Structural characterization
The presence of lanthionine, the structural characteristic trait
of lantibiotics, was evidenced by LC-MS analysis. Amylolysin
was first hydrolyzed in acidic conditions and OPA derivatized
prior analysis (Figure 3 insert). In the resulting chromatogram,
compounds eluted at retention time of 13.2 min in amylolysin
hydrolysate and lanthionine standard samples, point out the
presence of lanthionine [27]. Moreover, m/z signals at 315
deduced from the MS spectra confirm that amylolysin is a
lantibiotic senso stricto (Figure 3, insert). Similar results were
obtained with the well-characterized lantibiotic nisin (data not
shown). Matrix-assisted laser desorption ionization time of flight
mass spectrometry analyses (MALDI-TOF) of purified
amylolysin allowed the determination of its molecular mass
(Figure 3). Signal at m/z of 3317.6 obtained in negative mode
of measurement highlighted a molecular mass of 3318.6 Da.
The absence of this particular molecular mass in proteomic
databases suggests that amylolysin could be a novel
compound not described to date.
Interaction with Lipid II
In silico analysis of AmlA highlighted the C15TLTWEC21
sequence as a putative interaction site between amylolysin and
the lipid II. In order to confirm this hypothesis, two experiments
were designed. In the first one, a direct amylolysin-lipid II
interaction was characterized while in the second the ability of
amylolysin to inhibit the transglycosylation reaction involved in
peptidoglycan synthesis was investigated [28]. In both
experiments, interactions were analyzed by thin layer
chromatography based on the utilization of [14C] lipid II. As
shown in Figure 4A, the delay of migration of the amylolysin-
lipid II complex compared to that of free lipid II traduced the
direct interaction between the two partners. By contrast,
inhibition of the transglycosylation reaction resulted in a not
polymerized lipid II that migrates compared to polymerized
form remaining at the origin (Figure 4B).
Discussion
The majority of the bacteriocins described to date are from
lactic bacteria with nisin, used commercially in many countries
as preservative in food products [29], being the best
characterized compound. However, its sensitivity to proteases,
its low solubility above pH 6 and emergence of nisin resistant
strains, point out the need for alternative producer organisms
[30]. In regards to their high level of protease production,
Bacillus sp. has been considered as interesting alternative
source for antimicrobial peptides with increased protease
tolerance. In our laboratory, B. amyloliquefaciens GA1 has
been characterized for its ability to produce antimicrobial
metabolites [18]. Beside polyketides (PKs) and non-ribosomally
synthesized peptides (NRPs), GA1 was found to produce
amylolysin, a bacteriocin that is less sensitive to meat
proteases than nisin [17].
The prerequisites for the molecular characterization of
amylolysin was to scale-up and to adapt the production
process previously reported [17]. In addition, a GAI derivative
RFB136 mutant, unable to produce NRPs and PKs, was used
Figure 2.  Characterization of the RFB137 mutant.  The RP-HPLC chromatogram of concentrated supernatant of GA1 is in red
and that of the ΔamlA RFB137 mutant is in black. Insert: Antimicrobial activity of concentrated supernatant (10 µl) from GA1 and
RFB137 strains on LB agar plates seeded with M. luteus ATCC 9341.
doi: 10.1371/journal.pone.0083037.g002
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to prevent contaminations by other antimicrobial compounds
during the purification process.
The thermo-stability and pH tolerance together with the
structural characterization by LC-MS demonstrated that
amylolysin belongs to the class I bacteriocin family. Moreover,
the presence of one unique AmlM modification enzyme and an
AmlT transport protein with a peptidase-like associated domain
suggests that amylolysin belongs to the type-B lantibiotics. The
Figure 3.  MALDI-TOF MS and LC-MS analysis of amylolysin.  Mass spectrum of purified amylolysin sample was recorded in
negative mode. Insert: LC-MS chromatograms of commercial lanthionine standard and amylolysin hydrolysate. Intensity (%, Y-
scale) was recorded by setting the SQD mass analyzer on the specific mass of lanthionine (315 Da).
doi: 10.1371/journal.pone.0083037.g003
Figure 4.  Interation with lipid.  II. (A) Direct interaction of amylolysin with lipid II. Both compounds were incubated in DMSO/1-
octanol mixture (60/40 v/v) for 1 hour at room temperature before being subjected to TCL using a butanol/acetic acid/pyridine/water
mixture (15/3/12/10, v/v/v/v) as mobile phase. (B) Inhibition of the transglycosylation reaction. Amylolysin, lipid II and
glycosyltransferase were incubated for one hour before being subjected to TLC using a mixture of methanol/chloroform/ammoniac/
water (88/48/10/1, v/v/v/v) as mobile phase. [14C] lipid II was detected with a Molecular Imager FX system. Direction of solvent
migration during TLC is indicated by the arrow.
doi: 10.1371/journal.pone.0083037.g004
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absence of significant similarity between AmlA and bacteriocins
reported in BACTIBASE and Antimicrobial Peptide Database,
points out that amylolysin corresponds to a novel lantibiotic not
described to date. Reports on type-B lantibiotic from B.
amyloliquefaciens are scarce. So far, a gene cluster for
lantibiotic synthesis has been reported in B. amyloliquefaciens
subsp. plantarum strain YAU B9601-Y2 [31]. Beside this,
mersacidin production has been reported recently in B.
amyloliquefaciens subsp. plantarum B6901-Y2 and B.
amyloliquefaciens HIL Y-85,54728 [7,15,16]. The biosynthetic
cluster consists in a structural gene mrsA, together with gene
mrsM, involved in posttranslational modifications of the
mersacidin prepeptide; mrsT, coding for a transporter with
associated protease domain. The immunity genes mrsF, mrsE
and mrsG and the regulatory genes mrsR1, mrsR2 and mrsK2,
respectively, are also present. The two-component regulatory
system MrsR2/MrsK2 is mainly involved in immunity and self-
induction of mersacidin biosynthesis [32] whereas Mrs1 was
found essential for mersacidin production [33]. The presence of
genes involved in mersacidin self-protection has been also
detected in the genome of B. amyloliquefaciens FZB42 [34].
Despite that strain FZB42 is unable to produce mersacidin, it
has been used recently as a host cell for the transfer of the
mersacidin biosynthesis genes from B. amyloliquefaciens HIL
Y-85,54728 [15].
A close inspection of amlA sequence showed that it codes
for a 60 residues prepeptide with a specific G26GGG29 motif.
Type-B lantibiotics are known to possess leader sequences
ranging from 15 to 40 amino acids that are processed within
G(G/A/S)\XX motif. Thus, the G26GGG29 sequence found in
AmlA is the best candidate for processing site of the signal
peptide. However, the presence of four glycine residues allows
three possibilities for this processing (i.e. after glycine at
position 27, 28 and 29, respectively). MALDI-TOF
measurement has highlighted a mature AmlA peptide of 3318
Da that is consistent with a cleavage by AmlM after G29.
Thioether bridging patterns have been determined for several
type-B lantibiotics including lacticin 3147 [35] and haloduracin
[21]. Off these, the conserved CTxTxEC motif was found
involved in the formation of one Lan residue and two MeLan
creating the three-dimensional structure responsible for the
interaction with lipid II. Based on sequence alignment with α-
peptide of lacticin 3147 and haloduracin, it is likely that these
posttranslational modifications in amylolysin occur between
amino acid 36-44, 46-49 and 47-52 of the mature peptide,
respectively (Figure 1C). In addition, AmlA is characterized by
a mass that is consistent, with two possible Dhb residues at
amino acid position 55 and 57. Structurally, amylolysin seems
more related to α-peptide of two-component lantibiotics
compared to other lantibiotics described among the Bacillus
genus such as mersacidin or subtilin.
For most of the lantibiotics from Bacillus sp. described so far,
immunity is conferred by LanI and/or LanFEG proteins, with
exception of entianin and lacticin 3147 whose immunity seems
to be supported by EntG/EntI and LtnEF/LtnI proteins,
respectively [10,36] Moreover, in gallidermin producer strain,
an additional LanH protein, which serves as an ancillary protein
for the LanFE protein, has been described [37].
Mechanistically, LanI peptides are thought to function by
lantibiotic interception or target shielding [12,38] whereas
LanFE(G) proteins form ABC transporter of two or three
subunits with LanF being the ATP-binding domain [39]. In
lacticin 3147 producer strains, it has been shown that LtnE and
LtnF play an important role in immunity mechanism even at a
greater degree than LtnI. From this viewpoint, amylolysin gene
cluster is also atypical. Only two genes, namely AmlF and
AmlE, have been detected in GA1 strain suggesting that
immunity to amylolysin is ensured by a two-component ABC
transporter. The immunity mechanism is therefore somewhat
different from that found in B. amyloliquefaciens for mersacidin
self-protection [15,16].
This first characterization of amylolysin highlights some
divergences with the one-component type-B lantibiotic usually
produced by Bacillus sp. However, structural as well as
mechanistic data are still lacking to deeply characterize this
promising lantibiotics. The fact that amylolysin interacts with
lipid II, is certainly a first element to explain its biological mode
of action. Experiments are in progress to get those lacking
information.
Materials and Methods
Bacterial strains, culture media and general genetic
techniques
Bacillus amyloliquefaciens GA1 was used for amylolysin
production [17]. The different bacterial and hyphal isolates
used as indicator strains are listed in table 1. Escherichia coli
DH5α (Promega, Madisson, WI, USA) was used for
transformation and amplification of recombinant plasmid DNA
according standard procedures [40]. B. amyloliquefaciens GA1
was transformed as described elsewhere [41]. Luria-Bertani
(LB), brain-heart (BH), de Man-Rogosa-Sharpe (MRS), and
YPD media were of commercial origin (Becton-Dickinson, Le
pont de Chaix, France). Microbial growth was monitored by
optical density measurement at 600 nm (OD600). Genomic DNA
was purified using the Wizard genomic purification kit
(Promega). PCR amplifications were performed with Fideli Taq
polymerase (USB Corporation, Cleveland, OH, USA) and
amplified fragments were purified with the Qiagen purification
kit (Hilden, Germany). PCR fragments were cloned into pGEM-
T-easy vector prior sequencing at GIGA Genomics Facilities
(University of Liège, Liège, Belgium). Primers used for PCR
amplifications, plasmids and bacterial strains are listed in Table
S1. For similarity searches, the FastA program [42] was used
to scan UniProtKB/Swiss-Prot and UniProtKB/TrEMBL
databases. Sequence alignments were generated using
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and
manually adjusted in Genedoc (http://www.nrbsc.org/gfx/
genedoc/) to correct obvious mispairings. Predictions
terminators were performed using ARNold program [43]
whereas BPROM program was used for prediction of putative
promoter elements (http://linux1.softberry.com/all.htm). Blasts
analysis were performed at the NCBI website (http://
blast.ncbi.nlm.nih.gov/Blast.cgi).
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Amylolysin production, purification and quantification
Large-scale production of amylolysin was performed in a 80-
liters Bioflo 5000 bioreactor (New Brunswick) in a working
volume of 60 L of LB medium with strain RFB136 (a derivative
of strain GA1 unable to produce lipopeptides, see Text S1).
Cultures were conducted at 37 °C for 10 h at a stirring speed of
200 rpm and an aeration flow of 1 VVM (volume of air per
volume of medium per minute). Cell-free supernatant was
obtained by cross flow filtration using a hollow fiber cartridge
(0.45 µm, 8400 cm2, GE Healthcare) according to the
manufacturer’s recommendations. Amylolysin was purified in a
three steps procedure. Firstly, the antimicrobial peptide was
extracted from the culture supernatant using an Amberlite
XAD-16 resin (Sigma-Aldrich) and concentrated by rotary
evaporation. Amylolysin was subsequently purified in two steps
of reverse-phase RP-HPLC using a VP Nucleosil column (250
x 10 mm, 7 μm packing, Macherey-Nagel) and a Nucleodur
C18 column (50 x 4.6 mm, 5 μm packing, Macherey-Nagel) at
a flow rate of 2.5 and 1 ml min-1 of an acetonitrile/H2O mixture
(41/59, v/v), respectively. Amylolysin identification and
quantification were performed by RP-HPLC as described
previously [17].
Effect of enzyme, pH and temperature on amylolysin
activity
To evaluate sensitivity to proteases, purified amylolysin
samples were quantified by RP-HPLC after 24h of incubation at
37°C with proteinase K and pronase (10 µg/ml, Sigma-Aldrich).
Heat stability was evaluated after incubation for 60 min at
various temperatures (25, 55, 65, 75 and 100 °C) whereas pH
sensitivity was evaluated after a 1h-incubation in 200 mM
HCl/KCl buffer (pH 2-3), acetate buffer (pH 4-6) and Tris buffer
(pH 7-9). After those treatments, the remaining amylolysin
activity was determined using the agar diffusion assays as
described elsewhere, using Micrococcus luteus ATCC 9341 as
an indicator strain.
Minimal inhibitory concentration determination
Minimal inhibitory concentration (MIC) was determined for an
array of bacterial and yeast strains by a microdilution method
following the Clinical and Laboratory Standard Institute (CLSI)
recommended procedure [44]. Briefly, the different indicator
strains were aerobically grown in 24-wells culture plates in the
presence of purified amylolysin at concentration ranging from
0.1 to 2.8 µM in the appropriate medium and temperature
conditions as stipulated in table 1. Each well was seeded at an
OD600 of 0.1. After 24 h of incubation, cell growth was
estimated based on OD600 measurements. The MIC values
were defined as the lowest amylolysin concentration that is
able to inhibit cell growth. Each experiment was performed in
triplicate.
Characterization of amylolysin biosynthesis genes
Identification of the genomic locus involved in amylolysin
biosynthesis was performed by inverse polymerase chain
reaction (IPCR) [19]. Briefly, 5 µg of purified genomic DNA of
B. amyloliquefaciens GA1 were first digested with restriction
enzyme PstI (1U/µg for 2h). The digested DNA was then
purified before being self-ligated using T4 DNA ligase
(Promega). PCR amplification was then performed using
primer pair RFO142/RFO143 and the self-ligation mixture as a
template with an elongation time of 10 min. The resulting PCR
fragment was then cloned into pGEM-T-easy vector and
sequenced by primer walking. The resulting sequence was
then used for Blast search for further characterization of the
amylolysin locus.
Disruption of amlA
Disruption of amlA was performed as described previously
[45]. Briefly, the 407 and 523 bp P and T fragment consisting of
part of the 3’ and 5’ amlA ORF were PCR-amplified using
primer pairs P2B4sens/P2B4rev and T2B4sens/T2B4rev,
respectively, and B. amyloliquefaciens GA1 genomic DNA as a
template. Primers P2B4rev and T2B4sens contain the rare
meganuclease I-SceI recognition sequence. P-ISceI and ISceI-
T fragments were then pooled and used as a template for
amplification of the P-ISceI-T cassette with primers P2B4sens
and P2B4rev. The resulting fragment was then cloned into
pGEM-T easy vector to generate RFPA1. The 1.6 kb fragment
encoding a kanamycin resistance gene was rescued from
RFP104 [41] by ISceI digestion and subcloned into RFPA1 at
the corresponding restriction site to yield RFPA2. The amlA
disruption cassette was finally obtained by PCR amplification
with primers pair P2B4sens/T2B4rev and RFPA2 as a template
and used, after purification, to transform B. amyloliquefaciens
RFB136. Transformants were selected on LB-kanamycin plates
(10 µg/ml). Integration by double-crossing event in the RFB136
strain was verified by analytical PCR using primer pair
P2B4sens/T2B4rev. The amlA-disrupted strain was
denominated RFB137.
Mass spectrometry
The molecular mass of the purified amylolysin was
determined by matrix-assisted laser desorption ionization-time
of flight (MALDI-TOF) mass spectrometry using a 4700
Proteomics analyzer (Applied Biosystem). Purified amylolysin
was mixed with an equal volume of α-cyanohydroxycinnamic
acid solution (10 mg/ml) and spotted onto the MALDI plate. The
analyzer was used at an acceleration voltage of 20 kV.
Samples were measured in the reﬂectron mode. Mass spectral
databases and proteomic tools were MassBank (http://
www.massbank.jp) and Prospector (http://
prospector.ucsf.edu/).
The presence of the modified amino acid lanthionine in
amylolysin was demonstrated by RP-HPLC coupled with single
quad mass spectrometer (HPLC Waters Alliance 2695/diode
array detector, coupled with Waters SQD mass analyzer) on a
X-terra MS column (150 x 2.1 mm, 3.5 μm packing, Waters)
after peptide hydrolysis (HCl 6 M, for 4 h à 145°C) and
derivatization with o-phthaldialdehyde (OPA) (Agilent
Technology) as described elsewhere [46]. Elution was
performed at a constant ﬂow rate of 0.25 ml min-1 and at 40°C,
with a gradient of acetonitrile (solvent B) in water acidiﬁed with
0.1% formic acid (solvent A) as follows: 0-2 min, 0% B; 2-7
min, 0 to 10% B; 7-17 min, 10 to 15% B; 17-19 min, 15 to 95%
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B). Compounds were ﬁrst identiﬁed on the basis of their
retention times compared with a commercial lanthionine
standard (Sigma-Aldrich). The identity of lanthionine was
subsequently conﬁrmed on the basis of the masses detected in
the SQD by setting electrospray ionization (positive ion)
conditions in the MS as source temperature, 130°C;
desolvation temperature, 250°C; nitrogen ﬂow, 500 l h-1; cone
voltage, 50 V.
Interaction with Lipid II
Radiolabelled UDP-MurNac-pentapeptide, thereafter [14C]
lipid II, was prepared in vitro using E. coli K12 purified
membrane from UDP-GlcNac and UDP-MurNAc-L-Ala-D-Glu-
meso-DAP-D-[14C]Ala-D-[14C]Ala and subsequently purified as
previously described [28]. Inhibition of glycosyl transferase
reaction was performed as described elsewhere [47] with some
modifications. Briefly, [14C] lipid II (2.5µM; 0.125µCi nmol-1),
amylolysin (0.2 µM), His-tag PBP1bγ from E. coli (15 nM) were
incubated in 25mM Tris-HCl (pH7,5), 0,5 % decyl PEG, 10 mM
MgCl2, 12% 1-octanol, 25 % DMSO for 1 hour at 30 °C. The
reaction products were separated by thin layer chromatography
(TLC) on silica plate (SilG, 250 µM thickness, Macherey-Nagel,
Duren, Germany) using a mixture of methanol/chloroform/
ammoniac/water (88/48/10/1, v/v/v/v) as mobile phase. For
interaction experiment, [14C] lipid II (2.5 µM; 0.125µCinmol-1)
and amylolysin (0.2 µM) were incubated in DMSO/1-octanol
mixture (60/40 v/v) for 1 hour at room temperature before being
subjected to TCL using a butanol/acetic acid/pyridine/water
mixture (15/3/12/10, v/v/v/v) as mobile phase. The radioactive
compounds were detected and analyzed with a Molecular
Imager FX system (Biorad Laboratories).
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